Capital Markets Event: View a recording and access materials presented at OXB’s Capital Markets Event held on 2nd June 2026.
VectorXcellerator: OXB has selected the first programmes to move forward through VectorXcellerator, supporting earlier collaboration in advanced therapies.
OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture.
News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category.
Visit our refreshed resource centre for the latest case studies, research posters and more.
